冠状动脉动脉瘤的管理和结果:患者一级系统性审查
Daler Rahimov1, Nayeem Nasher1, Danial Ahmad1
1Department of Cardiac Surgery, Thomas Jefferson University, Philadelphia, PA, USA.
Critical pathways in cardiology
|February 4, 2025
概括
冠状动脉动脉瘤 (CAAs) 带有状连接 (CAAF) 具有更高的破裂风险,但更好的生存率. 管理策略各不相同,但手术和干预方法对CAAs产生类似的生存结果.
科学领域:
- 心脏病学 心脏病学
- 血管外科 血管外科
- 医学研究 医学研究
背景情况:
- 缺乏冠状动脉动脉瘤 (CAA) 的标准化管理指南.
- 本研究量化分析了关于CAA管理的现有证据.
研究的目的:
- 为了比较CAAs的结果和管理策略,具有状连接 (CAAF) 与没有 (CAAO) 的CAAs.
- 为指导CAA治疗提供数据驱动的见解.
主要方法:
- 对431个CAA病例报告/病例系列进行系统电子搜索,其中包括488名患者.
- 提取和分析患者级数据,比较CAAF和CAO子组.
- 卡普兰-梅尔生存分析和基于动脉瘤特征的危险评估.
主要成果:
- 与CAAO患者相比,CAAF患者的动脉瘤直径中位数更高,破裂风险明显增加.
- 胸痛是CAAO中更频繁出现的症状,而手术是CAAF的主要治疗方法.
- 尽管破裂风险较高,但CAAF显示出更有利的生存趋势,死亡率与两组动脉瘤直径相关.
结论:
- CAAF具有较高的破裂风险,但可能比CAAO更好的生存率.
- 应对CAA的管理应根据管的存在或不存在量身定制.
- 对CAAs的手术和干预管理策略都导致可比的生存率.
相关概念视频
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
Aneurysm III: Interprofessional Care
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
Aneurysm IV: Nursing Management
Vigilant monitoring for aneurysm rupture is essential for patients undergoing aortic surgery.Preoperative Nursing ManagementContinuously monitor the patient for manifestations of aneurysm rupture, such as pallor, weakness, tachycardia, hypotension, abdominal, back, groin, or periumbilical pain, changes in consciousness, and a pulsating abdominal mass. Regularly assess the patient's peripheral pulses.Instruct the patient to consume a clear liquid diet the day before surgery and administer...


